• Join Today!

Become a member and connect with:

  • An Active Online Community
  • Articles and Advice on SCD
  • Help Understanding Clinical Trials

California’s Stem Cell Agency Invests in Stem Cell-Based Therapies Targeting Sickle Cell Disease and Cancer


The California Institute for Regenerative Medicine (CIRM), California’s Stem Cell Agency, today invested almost $10 million in stem cell research targeting sickle cell disease and cancer at its February Board meeting.

The CIRM Board awarded $5.74 million to the City of Hope to fund a Phase 1 clinical trial testing a stem cell-based therapy for adult patients with severe sickle cell disease (SCD). SCD refers to a group of inherited blood disorders that cause red blood cells to take on an abnormal, sickle shape. Sickle cells clog blood vessels and block the normal flow of oxygen-carrying blood to the body’s tissues. Patients with SCD have a reduced life expectancy and experience various complications including anemia, stroke, organ damage, and bouts of excruciating pain.

https://www.onescdvoice.com/wp-content/uploads/2018/08/logo-cirm-2_0.png

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close